title: Lipoprotein lipase activity is favoured by peritoneal dialysis compared to hemodialysis.
abstract: BACKGROUND
  The lipoprotein lipase (LPL) pool is reduced by 50% in patients on hemodialysis (HD). LPL release by tinzaparin has not been investigated for peritoneal dialysis (PD). Therefore, the aim of this study was to investigate if tinzaparin differently alters the pool of LPL and triglyceride levels of patients on HD versus PD.
  
  
  METHODS
  Thirty-two patients on chronic PD or HD were matched to nearest age and gender. In order to release and thereby estimate the endothelial pool of LPL, all patients received a bolus of tinzaparin (75 units/kg). Blood samples were drawn for analysis of LPL activity and triglycerides (TG) between the groups.
  
  
  RESULTS
  The peak level of LPL released at 40 min after tinzaparin was similar in PD and HD patients. At 180 min, a slightly higher median level of LPL activity was noted in the PD patients (6.1 mU/mL (n = 6) versus 3.4 mU/mL (n = 16), p = 0.005). The TG concentration in plasma at 40 min was reduced relatively more in the PD patients than in the HD patients (p < 0.05). At 180 min, TG had returned to start levels in HD patients while they were still lowered in PD patients.
  
  
  CONCLUSIONS
  The negative effect of uraemia on the LPL pool in HD patients, known from other studies, here is shown to be similar in PD patients. Tinzaparin administration releases the LPL pool during each HD but does not cause an exhaustion of the LPL system over time. In contrast to HD, the LPL pool is not altered during PD.
authors.affiliation: Department of Public Health and Clinical Medicine, Umeå University , Umeå , Sweden.
authors.forename: Dana
authors.initials: D
authors.lastname: Mahmood
authors.forename: Solveig
authors.initials: S
authors.lastname: Nilsson
authors.forename: Gunilla
authors.initials: G
authors.lastname: Olivecrona
authors.forename: Bernd
authors.initials: B
authors.lastname: Stegmayr
mesh_terms: D000368:Aged; D005260:Female; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008071:Lipoprotein Lipase / Q000097:blood*; D008297:Male; D008875:Middle Aged; D010530:Peritoneal Dialysis; D006435:Renal Dialysis; D000078222:Tinzaparin; D014280:Triglycerides / Q000097:blood; D014511:Uremia / Q000097:blood
chemical_list: D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D014280:Triglycerides; D000078222:Tinzaparin; D008071:Lipoprotein Lipase
keywords: Lipoprotein lipase; Peritoneal dialysis; anticoagulant drugs; hemodialysis; tinzaparin sodium; triglycerides